Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Best Practices in Non-Toxic Sanitizing for Businesses

Which cleaning supplies are stocked in the janitor’s closet? Typically, that’s a decision that has been made down the org chart, if anyone is making the call at all. Now, during the coronavirus pandemic, the buck may stop at the very top when it comes to the choice of disinfectants or cleaning products. With…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
Best Practices in Non-Toxic Sanitizing for Businesses

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Which cleaning supplies are stocked in the janitor’s closet? Typically, that’s a decision that has been made down the org chart, if anyone is making the call at all.

Now, during the coronavirus pandemic, the buck may stop at the very top when it comes to the choice of disinfectants or cleaning products.

With public health a top priority, decision-makers need to be educating themselves, said John Shanahan, President and CEO of Ionogen.

“Building owners and managers have to start reading safety data sheets. They have to start understanding what toxins are being sprayed in their buildings,” Shanahan said. “In the case of commercial buildings and even restaurants, what they need to do is look at what innovation is here. What’s coming out of COVID that will allow them to reopen, have limited worker illness and improve the overall health of the building?”

One of those solutions is similar to innovations in swimming pools, where we’ve replaced chlorine and bleach with rock salt in order to kill bacteria and viruses.

“Now imagine if you could take the same concept and put a dry fog in a restaurant or a movie theater or in a hotel room. It’s a nice dry fog. It doesn’t look like London, but it’s a little bit of haze in the air,” Shanahan said. “Now someone comes in with the worst case of COVID or measles or tuberculous, and they sneeze or cough. Just like the swimming pool, that would take that virus out of the air, it would knock it right down so the virus can’t travel to a desktop, the virus can’t travel to me and get caught in my upper respiratory system.”

It’s on business leaders to make sure their employees and guests are safe, so research into what chemicals are present and what they do will be critical as businesses reopen.

For the latest news, videos, and podcasts in the Building Management Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512